Back to All News

Prior Press Coverage of HOPO's Foundational Work

Mar 1, 2020
UC Berkeley
Rebecca Abergel elected a fellow of the American Association for the Advancement of Science
The Daily Californian
Berkeley Lab creates anti-nuclear contamination pill to help MRI patients
Berkeley Lab News
A Single Dose for Good Measure: How an Anti-Nuclear-Contamination Pill Could Also Help MRI Patients
Nature
Julian Rees and Rebecca Abergel Publish Proof-of-Concept Study Showing Effective Treatment for Gadolinium Contamination
MIT Technology Review
Rebecca Abergel named to MIT Technology Review’s list of Innovators Under 35
Berkeley Lab News
Responding to the Radiation Threat
More News & Publications
HOPO Therapeutics awarded BARDA contract of up to $226 million
Oct 3, 2024
HOPO Therapeutics awarded BARDA contract of up to $226 million
HOPO Therapeutics jointly awarded $1.78M ARPA-E Grant
Nov 2, 2023
HOPO Therapeutics jointly awarded $1.78M ARPA-E Grant
Jun 9, 2023
Phase 1 Clinical Trial of HOPO 14-1 Now Recruiting
See all news
Stay up to date with research and development updates, news, and more on our mailing list.
HOPO Therapeutics
About UsScienceProgramsNews & PublicationsContact
5858 Horton St. Suite 393 
 Emeryville CA, 94608
info@hopotx.com
+1 (510) 239-3180
A Subsidiary of HOPO Technologies Group
© 2025 HOPO Therapeutics, Inc. All Rights Reserved.
TermsPrivacyDisclaimers